Marker Therapeutics Inc (FRA:GX1)
€ 3.12 -0.02 (-0.64%) Market Cap: 29.51 Mil Enterprise Value: 13.31 Mil PE Ratio: 0 PB Ratio: 3.40 GF Score: 43/100

Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 16, 2019 / 05:40PM GMT
Release Date Price: €0.01
Peter L. Hoang
Marker Therapeutics, Inc. - President, CEO & Director

(technical difficulty)

Hoang, I'm the President and Chief Executive Officer of Marker Therapeutics. It's our great pleasure as a company to be able to present here today and tell you a little bit about what we have been doing as a company. So we should have our presentation projected momentarily here. Let me just say that we're a public company, and so I encourage you to refer to our public filings for a comprehensive list of risk factors as we will be making forward-looking statements today.

So Marker Therapeutics is, I think, a very, very different cell therapy company from most of the cell therapy companies that are advancing products in immuno-oncology today. In that what we are creating is a multi-antigen specific product that targets not only a single epitope of a single-target antigen, but potentially multiple target epitopes. In fact, our product seeks to create an omni epitope product across up to 5 tumor-associated antigens. In fact, our current products average around 4,000 different T cell clonotypes.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot